1. Home
  2. NXL vs CISS Comparison

NXL vs CISS Comparison

Compare NXL & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXL
  • CISS
  • Stock Information
  • Founded
  • NXL 2010
  • CISS 2022
  • Country
  • NXL United States
  • CISS Greece
  • Employees
  • NXL N/A
  • CISS N/A
  • Industry
  • NXL Medical Specialities
  • CISS Marine Transportation
  • Sector
  • NXL Health Care
  • CISS Consumer Discretionary
  • Exchange
  • NXL Nasdaq
  • CISS Nasdaq
  • Market Cap
  • NXL 21.0M
  • CISS 2.8M
  • IPO Year
  • NXL 2022
  • CISS N/A
  • Fundamental
  • Price
  • NXL $1.06
  • CISS $3.48
  • Analyst Decision
  • NXL Strong Buy
  • CISS
  • Analyst Count
  • NXL 1
  • CISS 0
  • Target Price
  • NXL $5.00
  • CISS N/A
  • AVG Volume (30 Days)
  • NXL 77.9K
  • CISS 96.2K
  • Earning Date
  • NXL 08-07-2025
  • CISS 08-21-2025
  • Dividend Yield
  • NXL N/A
  • CISS N/A
  • EPS Growth
  • NXL N/A
  • CISS N/A
  • EPS
  • NXL N/A
  • CISS N/A
  • Revenue
  • NXL $131,065.00
  • CISS $38,174,754.00
  • Revenue This Year
  • NXL $79.59
  • CISS N/A
  • Revenue Next Year
  • NXL $334.65
  • CISS N/A
  • P/E Ratio
  • NXL N/A
  • CISS N/A
  • Revenue Growth
  • NXL N/A
  • CISS N/A
  • 52 Week Low
  • NXL $0.59
  • CISS $2.85
  • 52 Week High
  • NXL $4.49
  • CISS $23.25
  • Technical
  • Relative Strength Index (RSI)
  • NXL 46.92
  • CISS 49.46
  • Support Level
  • NXL $0.96
  • CISS $3.27
  • Resistance Level
  • NXL $1.10
  • CISS $3.59
  • Average True Range (ATR)
  • NXL 0.07
  • CISS 0.15
  • MACD
  • NXL 0.02
  • CISS 0.02
  • Stochastic Oscillator
  • NXL 77.81
  • CISS 71.70

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.

Share on Social Networks: